P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden
IntroductionPatients with hepatitis C (HCV) related cirrhosis should undergo 6 monthly hepatocellular carcinoma (HCC) surveillance, as this has been shown to be effective in increasing longevity where the incidence of HCC is greater than 1.5% per year.1 NHS England define HCV cirrhosis on Fibroscan®...
Gespeichert in:
Veröffentlicht in: | Gut 2021-01, Vol.70 (Suppl 1), p.A237-A238 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A238 |
---|---|
container_issue | Suppl 1 |
container_start_page | A237 |
container_title | Gut |
container_volume | 70 |
creator | Powles, Sam Pallett, Scott Finch, Alexandra Vaikunthanathan, Trishan Jones, Fiona Morgan, Helen Verma, Suman Foxton, Matthew |
description | IntroductionPatients with hepatitis C (HCV) related cirrhosis should undergo 6 monthly hepatocellular carcinoma (HCC) surveillance, as this has been shown to be effective in increasing longevity where the incidence of HCC is greater than 1.5% per year.1 NHS England define HCV cirrhosis on Fibroscan®/transient elastography (TE) as a liver stiffness measure (LSM) >11.5 kPa2 prior to commencing direct-acting antiviral (DAA) treatment. AASLD guidelines define HCV cirrhosis as a LSM score of >12.5 kPa, and >14 kPa has been used in other studies.3 This lower score by NHS England may lead to a higher burden of HCC surveillance in HCV patients. This study aimed to assess the impact of HCC risk if higher LSM measurements are used to define cirrhosis, and to evaluate the impact on the subsequent ultrasound (US) surveillance burden.Methods100 patients with HCV with a LSM >11.5 kPa on TE using the local treatment database were identified, and from this 53 patients had a complete set of data at the time of the pre-DAA treatment Fibroscan® allowing a 3 year HCC percentage risk to be calculated using the validated HCC calculator.4 The cirrhosis parameter within the risk score calculator was defined as a Fibroscan® score of either >11.5 kPa, >12.5 kPa, or >14 kPa, and comparisons were made of HCC risk between HCV cirrhosis and non-cirrhosis patients depending on LSM cut off for cirrhosis in each of these groups. Statistical significance between cirrhotic and non-cirrhotic HCC risk was performed using a Mann-Whitney test, and reduction in US surveillance burden was calculated as a percentage.ResultsWhen HCV cirrhosis was defined as a LSM of >12.5 kPa, the 3 year risk of HCC was 2.91% compared to non-cirrhosis patients (LSM ≤12.5 kPa) who had a risk of 0.15% (p = 14 kPa conferred a 3 year HCC risk of 3.07% compared to non-cirrhosis (LSM ≤14 kPa) who had a risk of 0.24% (p = 0.0001). In both these groups where a higher LSM cut off for cirrhosis has been used, there was a significantly higher 3 year risk of HCC in the cirrhosis patients, and no patients within the non-cirrhosis groups had a 3 year HCC risk >1.5%.Abstract P381 Table 1 Cut off for cirrhosis on TE (LSM in kPa) Median 3 yr HCC risk (%) HCV cirrhosis HCV non-cirrhosis >11.5 2.46 - >12.5 2.91 0.15 >14 3.07 0.24 Increasing the TE definition of cirrhosis from >11.5 kPa to >14 kPa in this cohort led to a 42.7% reduction in 6 monthly US surveillance in this cohort.Conc |
doi_str_mv | 10.1136/gutjnl-2020-bsgcampus.455 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2479632371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479632371</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1245-da822af3bfa29f009bb859ce5148868e1708998a33356870a1925634f6c0b043</originalsourceid><addsrcrecordid>eNo90N9KwzAUBvAgCs7pO0S87szfNrmU6pww0IvhbUiytEtp05qswu688UV9EjsmXh04fN858APgFqMFxjS_r8d9E9qMIIIyk2qru2FMC8b5GZhhlouMEiHOwQwhXGS8YPISXKXUIISEkHgGtm9U4J-v70dX-eBDDVflO7Q-xl2ffILmAJfexD5ZHWCyfXRwpxPUMPk6-MpP6z303aDtHvZhKpcwjfHT-bbVwTpoxrh14RpcVLpN7uZvzsFm-bQpV9n69fmlfFhnBhPGs60WhOiKmkoTWSEkjRFcWscxEyIXDhdISCk0pZTnokAaS8JzyqrcIoMYnYO709kh9h-jS3vV9GMM00dFWCFzSmiBpxQ7pUzXqCH6TseDwkgdOdWJUx051T-nmjjpL7tZbT0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479632371</pqid></control><display><type>article</type><title>P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden</title><source>PubMed Central</source><creator>Powles, Sam ; Pallett, Scott ; Finch, Alexandra ; Vaikunthanathan, Trishan ; Jones, Fiona ; Morgan, Helen ; Verma, Suman ; Foxton, Matthew</creator><creatorcontrib>Powles, Sam ; Pallett, Scott ; Finch, Alexandra ; Vaikunthanathan, Trishan ; Jones, Fiona ; Morgan, Helen ; Verma, Suman ; Foxton, Matthew</creatorcontrib><description>IntroductionPatients with hepatitis C (HCV) related cirrhosis should undergo 6 monthly hepatocellular carcinoma (HCC) surveillance, as this has been shown to be effective in increasing longevity where the incidence of HCC is greater than 1.5% per year.1 NHS England define HCV cirrhosis on Fibroscan®/transient elastography (TE) as a liver stiffness measure (LSM) >11.5 kPa2 prior to commencing direct-acting antiviral (DAA) treatment. AASLD guidelines define HCV cirrhosis as a LSM score of >12.5 kPa, and >14 kPa has been used in other studies.3 This lower score by NHS England may lead to a higher burden of HCC surveillance in HCV patients. This study aimed to assess the impact of HCC risk if higher LSM measurements are used to define cirrhosis, and to evaluate the impact on the subsequent ultrasound (US) surveillance burden.Methods100 patients with HCV with a LSM >11.5 kPa on TE using the local treatment database were identified, and from this 53 patients had a complete set of data at the time of the pre-DAA treatment Fibroscan® allowing a 3 year HCC percentage risk to be calculated using the validated HCC calculator.4 The cirrhosis parameter within the risk score calculator was defined as a Fibroscan® score of either >11.5 kPa, >12.5 kPa, or >14 kPa, and comparisons were made of HCC risk between HCV cirrhosis and non-cirrhosis patients depending on LSM cut off for cirrhosis in each of these groups. Statistical significance between cirrhotic and non-cirrhotic HCC risk was performed using a Mann-Whitney test, and reduction in US surveillance burden was calculated as a percentage.ResultsWhen HCV cirrhosis was defined as a LSM of >12.5 kPa, the 3 year risk of HCC was 2.91% compared to non-cirrhosis patients (LSM ≤12.5 kPa) who had a risk of 0.15% (p = <0.0001). HCV cirrhosis defined as a LSM score of >14 kPa conferred a 3 year HCC risk of 3.07% compared to non-cirrhosis (LSM ≤14 kPa) who had a risk of 0.24% (p = 0.0001). In both these groups where a higher LSM cut off for cirrhosis has been used, there was a significantly higher 3 year risk of HCC in the cirrhosis patients, and no patients within the non-cirrhosis groups had a 3 year HCC risk >1.5%.Abstract P381 Table 1 Cut off for cirrhosis on TE (LSM in kPa) Median 3 yr HCC risk (%) HCV cirrhosis HCV non-cirrhosis >11.5 2.46 - >12.5 2.91 0.15 >14 3.07 0.24 Increasing the TE definition of cirrhosis from >11.5 kPa to >14 kPa in this cohort led to a 42.7% reduction in 6 monthly US surveillance in this cohort.ConclusionsUsing the pre-DAA treatment HCV definition for cirrhosis (LSM >11.5 kPa) may be causing an unnecessary number of patients to undergo US surveillance, and changing the Fibroscan® definition of cirrhosis may have significant cost benefit. This needs to be assessed in a larger cohort.ReferencesMarrero, et al. Hepatology. 2018.NHS England. Clinical Commissioning Policy Statement. 2015.Tsochatzis, et al. J Hepatol. 2011.Ioannou, et al. J Hepatol. 2018.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2020-bsgcampus.455</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Cirrhosis ; Hepatitis C ; Hepatocellular carcinoma ; Liver cirrhosis ; Patients ; Surveillance ; Ultrasound</subject><ispartof>Gut, 2021-01, Vol.70 (Suppl 1), p.A237-A238</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Powles, Sam</creatorcontrib><creatorcontrib>Pallett, Scott</creatorcontrib><creatorcontrib>Finch, Alexandra</creatorcontrib><creatorcontrib>Vaikunthanathan, Trishan</creatorcontrib><creatorcontrib>Jones, Fiona</creatorcontrib><creatorcontrib>Morgan, Helen</creatorcontrib><creatorcontrib>Verma, Suman</creatorcontrib><creatorcontrib>Foxton, Matthew</creatorcontrib><title>P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden</title><title>Gut</title><description>IntroductionPatients with hepatitis C (HCV) related cirrhosis should undergo 6 monthly hepatocellular carcinoma (HCC) surveillance, as this has been shown to be effective in increasing longevity where the incidence of HCC is greater than 1.5% per year.1 NHS England define HCV cirrhosis on Fibroscan®/transient elastography (TE) as a liver stiffness measure (LSM) >11.5 kPa2 prior to commencing direct-acting antiviral (DAA) treatment. AASLD guidelines define HCV cirrhosis as a LSM score of >12.5 kPa, and >14 kPa has been used in other studies.3 This lower score by NHS England may lead to a higher burden of HCC surveillance in HCV patients. This study aimed to assess the impact of HCC risk if higher LSM measurements are used to define cirrhosis, and to evaluate the impact on the subsequent ultrasound (US) surveillance burden.Methods100 patients with HCV with a LSM >11.5 kPa on TE using the local treatment database were identified, and from this 53 patients had a complete set of data at the time of the pre-DAA treatment Fibroscan® allowing a 3 year HCC percentage risk to be calculated using the validated HCC calculator.4 The cirrhosis parameter within the risk score calculator was defined as a Fibroscan® score of either >11.5 kPa, >12.5 kPa, or >14 kPa, and comparisons were made of HCC risk between HCV cirrhosis and non-cirrhosis patients depending on LSM cut off for cirrhosis in each of these groups. Statistical significance between cirrhotic and non-cirrhotic HCC risk was performed using a Mann-Whitney test, and reduction in US surveillance burden was calculated as a percentage.ResultsWhen HCV cirrhosis was defined as a LSM of >12.5 kPa, the 3 year risk of HCC was 2.91% compared to non-cirrhosis patients (LSM ≤12.5 kPa) who had a risk of 0.15% (p = <0.0001). HCV cirrhosis defined as a LSM score of >14 kPa conferred a 3 year HCC risk of 3.07% compared to non-cirrhosis (LSM ≤14 kPa) who had a risk of 0.24% (p = 0.0001). In both these groups where a higher LSM cut off for cirrhosis has been used, there was a significantly higher 3 year risk of HCC in the cirrhosis patients, and no patients within the non-cirrhosis groups had a 3 year HCC risk >1.5%.Abstract P381 Table 1 Cut off for cirrhosis on TE (LSM in kPa) Median 3 yr HCC risk (%) HCV cirrhosis HCV non-cirrhosis >11.5 2.46 - >12.5 2.91 0.15 >14 3.07 0.24 Increasing the TE definition of cirrhosis from >11.5 kPa to >14 kPa in this cohort led to a 42.7% reduction in 6 monthly US surveillance in this cohort.ConclusionsUsing the pre-DAA treatment HCV definition for cirrhosis (LSM >11.5 kPa) may be causing an unnecessary number of patients to undergo US surveillance, and changing the Fibroscan® definition of cirrhosis may have significant cost benefit. This needs to be assessed in a larger cohort.ReferencesMarrero, et al. Hepatology. 2018.NHS England. Clinical Commissioning Policy Statement. 2015.Tsochatzis, et al. J Hepatol. 2011.Ioannou, et al. J Hepatol. 2018.</description><subject>Cirrhosis</subject><subject>Hepatitis C</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cirrhosis</subject><subject>Patients</subject><subject>Surveillance</subject><subject>Ultrasound</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNo90N9KwzAUBvAgCs7pO0S87szfNrmU6pww0IvhbUiytEtp05qswu688UV9EjsmXh04fN858APgFqMFxjS_r8d9E9qMIIIyk2qru2FMC8b5GZhhlouMEiHOwQwhXGS8YPISXKXUIISEkHgGtm9U4J-v70dX-eBDDVflO7Q-xl2ffILmAJfexD5ZHWCyfXRwpxPUMPk6-MpP6z303aDtHvZhKpcwjfHT-bbVwTpoxrh14RpcVLpN7uZvzsFm-bQpV9n69fmlfFhnBhPGs60WhOiKmkoTWSEkjRFcWscxEyIXDhdISCk0pZTnokAaS8JzyqrcIoMYnYO709kh9h-jS3vV9GMM00dFWCFzSmiBpxQ7pUzXqCH6TseDwkgdOdWJUx051T-nmjjpL7tZbT0</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Powles, Sam</creator><creator>Pallett, Scott</creator><creator>Finch, Alexandra</creator><creator>Vaikunthanathan, Trishan</creator><creator>Jones, Fiona</creator><creator>Morgan, Helen</creator><creator>Verma, Suman</creator><creator>Foxton, Matthew</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>202101</creationdate><title>P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden</title><author>Powles, Sam ; Pallett, Scott ; Finch, Alexandra ; Vaikunthanathan, Trishan ; Jones, Fiona ; Morgan, Helen ; Verma, Suman ; Foxton, Matthew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1245-da822af3bfa29f009bb859ce5148868e1708998a33356870a1925634f6c0b043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cirrhosis</topic><topic>Hepatitis C</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cirrhosis</topic><topic>Patients</topic><topic>Surveillance</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Powles, Sam</creatorcontrib><creatorcontrib>Pallett, Scott</creatorcontrib><creatorcontrib>Finch, Alexandra</creatorcontrib><creatorcontrib>Vaikunthanathan, Trishan</creatorcontrib><creatorcontrib>Jones, Fiona</creatorcontrib><creatorcontrib>Morgan, Helen</creatorcontrib><creatorcontrib>Verma, Suman</creatorcontrib><creatorcontrib>Foxton, Matthew</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Powles, Sam</au><au>Pallett, Scott</au><au>Finch, Alexandra</au><au>Vaikunthanathan, Trishan</au><au>Jones, Fiona</au><au>Morgan, Helen</au><au>Verma, Suman</au><au>Foxton, Matthew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden</atitle><jtitle>Gut</jtitle><date>2021-01</date><risdate>2021</risdate><volume>70</volume><issue>Suppl 1</issue><spage>A237</spage><epage>A238</epage><pages>A237-A238</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><abstract>IntroductionPatients with hepatitis C (HCV) related cirrhosis should undergo 6 monthly hepatocellular carcinoma (HCC) surveillance, as this has been shown to be effective in increasing longevity where the incidence of HCC is greater than 1.5% per year.1 NHS England define HCV cirrhosis on Fibroscan®/transient elastography (TE) as a liver stiffness measure (LSM) >11.5 kPa2 prior to commencing direct-acting antiviral (DAA) treatment. AASLD guidelines define HCV cirrhosis as a LSM score of >12.5 kPa, and >14 kPa has been used in other studies.3 This lower score by NHS England may lead to a higher burden of HCC surveillance in HCV patients. This study aimed to assess the impact of HCC risk if higher LSM measurements are used to define cirrhosis, and to evaluate the impact on the subsequent ultrasound (US) surveillance burden.Methods100 patients with HCV with a LSM >11.5 kPa on TE using the local treatment database were identified, and from this 53 patients had a complete set of data at the time of the pre-DAA treatment Fibroscan® allowing a 3 year HCC percentage risk to be calculated using the validated HCC calculator.4 The cirrhosis parameter within the risk score calculator was defined as a Fibroscan® score of either >11.5 kPa, >12.5 kPa, or >14 kPa, and comparisons were made of HCC risk between HCV cirrhosis and non-cirrhosis patients depending on LSM cut off for cirrhosis in each of these groups. Statistical significance between cirrhotic and non-cirrhotic HCC risk was performed using a Mann-Whitney test, and reduction in US surveillance burden was calculated as a percentage.ResultsWhen HCV cirrhosis was defined as a LSM of >12.5 kPa, the 3 year risk of HCC was 2.91% compared to non-cirrhosis patients (LSM ≤12.5 kPa) who had a risk of 0.15% (p = <0.0001). HCV cirrhosis defined as a LSM score of >14 kPa conferred a 3 year HCC risk of 3.07% compared to non-cirrhosis (LSM ≤14 kPa) who had a risk of 0.24% (p = 0.0001). In both these groups where a higher LSM cut off for cirrhosis has been used, there was a significantly higher 3 year risk of HCC in the cirrhosis patients, and no patients within the non-cirrhosis groups had a 3 year HCC risk >1.5%.Abstract P381 Table 1 Cut off for cirrhosis on TE (LSM in kPa) Median 3 yr HCC risk (%) HCV cirrhosis HCV non-cirrhosis >11.5 2.46 - >12.5 2.91 0.15 >14 3.07 0.24 Increasing the TE definition of cirrhosis from >11.5 kPa to >14 kPa in this cohort led to a 42.7% reduction in 6 monthly US surveillance in this cohort.ConclusionsUsing the pre-DAA treatment HCV definition for cirrhosis (LSM >11.5 kPa) may be causing an unnecessary number of patients to undergo US surveillance, and changing the Fibroscan® definition of cirrhosis may have significant cost benefit. This needs to be assessed in a larger cohort.ReferencesMarrero, et al. Hepatology. 2018.NHS England. Clinical Commissioning Policy Statement. 2015.Tsochatzis, et al. J Hepatol. 2011.Ioannou, et al. J Hepatol. 2018.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/gutjnl-2020-bsgcampus.455</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0017-5749 |
ispartof | Gut, 2021-01, Vol.70 (Suppl 1), p.A237-A238 |
issn | 0017-5749 1468-3288 |
language | eng |
recordid | cdi_proquest_journals_2479632371 |
source | PubMed Central |
subjects | Cirrhosis Hepatitis C Hepatocellular carcinoma Liver cirrhosis Patients Surveillance Ultrasound |
title | P381 Defining HCV cirrhosis by Fibroscan score has a significant impact on HCC surveillance burden |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A09%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P381%E2%80%85Defining%20HCV%20cirrhosis%20by%20Fibroscan%20score%20has%20a%20significant%20impact%20on%20HCC%20surveillance%20burden&rft.jtitle=Gut&rft.au=Powles,%20Sam&rft.date=2021-01&rft.volume=70&rft.issue=Suppl%201&rft.spage=A237&rft.epage=A238&rft.pages=A237-A238&rft.issn=0017-5749&rft.eissn=1468-3288&rft_id=info:doi/10.1136/gutjnl-2020-bsgcampus.455&rft_dat=%3Cproquest_bmj_p%3E2479632371%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479632371&rft_id=info:pmid/&rfr_iscdi=true |